C
CVRx
Developed proprietary implantable technology for the treatment of high blood pressure and heart failure
About CVRx
CVRx, a pioneering medical technology company, focuses on enhancing cardiovascular health through innovative therapies. The company's flagship product, BAROSTIM NEO, is the first neuromodulation device designed to treat heart failure. Neuromodulation involves altering nerve activity by delivering electrical stimuli to specific nerves. This device targets baroreceptors, which are sensors in the cardiovascular system that help regulate blood pressure.
Read full description
CVRx primarily serves patients suffering from heart failure, a condition where the heart cannot pump blood effectively, leading to symptoms like fatigue, shortness of breath, and fluid retention. The company also collaborates closely with healthcare professionals, providing them with the tools and knowledge necessary to implement BAROSTIM THERAPY effectively.
Operating in the medical technology market, CVRx addresses a significant and growing need. Heart failure affects millions of people worldwide, and traditional treatments often fall short in managing the condition. By offering a novel solution, CVRx positions itself in a niche yet critical segment of the healthcare industry.
The business model of CVRx revolves around the development, manufacturing, and distribution of its BAROSTIM NEO device. The company generates revenue through the sale of these devices to hospitals and clinics. Additionally, CVRx provides comprehensive support programs to ensure patient access and reimbursement, which helps healthcare providers adopt and utilize the therapy more efficiently.
In summary, CVRx is dedicated to transforming the lives of heart failure patients through its groundbreaking BAROSTIM NEO device. By focusing on both patient outcomes and healthcare provider support, the company aims to make a significant impact on cardiovascular health.
At a glance
- Founded
- 2001
- Headquarters
- Minneapolis, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning CVRx.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about CVRx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CVRx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.